Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))

Taesik Gwag, Zhaojie Meng, Yipeng Sui, Robert N. Helsley, Se Hyung Park, Shuxia Wang, Richard N. Greenberg, Changcheng Zhou

Research output: Contribution to journalComment/debate

Abstract

It has come to our attention that there was a mistake in Fig. 6 in the published version of our manuscript. The mistake occurred during the publication process and has resulted in the labelling being inverted for the treatments with emtricitabine and efavirenz in the graph in Fig. 6A. Please see the corrected figure above. We apologize for any inconvenience caused.

Original languageEnglish
Pages (from-to)1003-1004
Number of pages2
JournalJournal of Hepatology
Volume74
Issue number4
DOIs
StatePublished - Apr 2021

Bibliographical note

Publisher Copyright:
© 2019 European Association for the Study of the Liver

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))'. Together they form a unique fingerprint.

Cite this